Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

卡那努马布 医学 内科学 危险系数 心肌梗塞 不利影响 安慰剂 随机对照试验 混淆 临床试验 置信区间 阿纳基纳 疾病 病理 替代医学
作者
Paul M. Ridker,Jean G. MacFadyen,Brendan M Everett,Peter Libby,Tom Y. Thuren,Robert J. Glynn,Paul M. Ridker,Jean G. MacFadyen,Brendan M Everett,Peter Libby,Tom Y. Thuren,Robert J. Glynn,John J.P. Kastelein,Wolfgang Köenig,Jacques J. Genest,Alberto J. Lorenzatti,John Varigos,Peter Siostrzonek,Peter Sinnaeve,Francisco Antônio Helfenstein Fonseca
出处
期刊:The Lancet [Elsevier BV]
卷期号:391 (10118): 319-328 被引量:919
标识
DOI:10.1016/s0140-6736(17)32814-3
摘要

Background Canakinumab, a monoclonal antibody targeting interleukin-1β, reduces inflammation and cardiovascular event rates with no effect on lipid concentrations. However, it is uncertain which patient groups benefit the most from treatment and whether reductions in the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) correlate with clinical benefits for individual patients. Methods The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) used computer-generated codes to randomly allocate 10 061 men and women with a history of myocardial infarction to placebo or one of three doses of canakinumab (50 mg, 150 mg, or 300 mg) given subcutaneously once every 3 months. In a prespecified secondary analysis designed to address the relationship of hsCRP reduction to event reduction in CANTOS, we evaluated the effects of canakinumab on rates of major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality according to on-treatment concentrations of hsCRP. We used multivariable modelling to adjust for baseline factors associated with achieved hsCRP and multiple sensitivity analyses to address the magnitude of residual confounding. The median follow-up was 3·7 years. The trial is registered with ClinicalTrials.gov, number NCT01327846. Findings Baseline clinical characteristics did not define patient groups with greater or lesser cardiovascular benefits when treated with canakinumab. However, trial participants allocated to canakinumab who achieved hsCRP concentrations less than 2 mg/L had a 25% reduction in major adverse cardiovascular events (multivariable adjusted hazard ratio [HRadj]=0·75, 95% CI 0·66–0·85, p<0·0001), whereas no significant benefit was observed among those with on-treatment hsCRP concentrations of 2 mg/L or above (HRadj=0·90, 0·79–1·02, p=0·11). For those treated with canakinumab who achieved on-treatment hsCRP concentrations less than 2 mg/L, cardiovascular mortality (HRadj=0·69, 95% CI 0·56–0·85, p=0·0004) and all-cause mortality (HRadj=0·69, 0·58–0·81, p<0·0001) were both reduced by 31%, whereas no significant reduction in these endpoints was observed among those treated with canakinumab who achieved hsCRP concentrations of 2 mg/L or above. Similar differential effects were found in analyses of the trial prespecified secondary cardiovascular endpoint (which additionally included hospitalisation for unstable angina requiring unplanned revascularisation) and in sensitivity analyses alternatively based on median reductions in hsCRP, on 50% or greater reductions in hsCRP, on the median percent reduction in hsCRP, in dose-specific analyses, and in analyses using a causal inference approach to estimate the effect of treatment among individuals who would achieve a targeted hsCRP concentration. Interpretation The magnitude of hsCRP reduction following a single dose of canakinumab might provide a simple clinical method to identify individuals most likely to accrue the largest benefit from continued treatment. These data further suggest that lower is better for inflammation reduction with canakinumab. Funding Novartis Pharmaceuticals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刘营营完成签到,获得积分10
刚刚
刚刚
爆米花的应助被aoao采纳,获得10
刚刚
刚刚
penghuiye完成签到,获得积分10
1秒前
壮观以松完成签到,获得积分10
1秒前
2秒前
Michael完成签到,获得积分10
2秒前
3秒前
pigeon发布了新的文献求助10
4秒前
林深沉完成签到,获得积分10
5秒前
5秒前
5秒前
霜沐发布了新的文献求助10
6秒前
zhen完成签到,获得积分10
6秒前
真不爱学习完成签到 ,获得积分10
6秒前
jackhlj完成签到,获得积分10
6秒前
6秒前
开朗天问完成签到,获得积分10
6秒前
yl完成签到,获得积分10
7秒前
suisui发布了新的文献求助10
7秒前
李君完成签到 ,获得积分10
7秒前
lifeline发布了新的文献求助30
7秒前
cdercder的应助被林深沉采纳,获得10
8秒前
linhongwei发布了新的文献求助20
8秒前
9秒前
10秒前
tszjw168发布了新的文献求助10
10秒前
峰峰发布了新的文献求助10
12秒前
Orange的应助被啊汪~采纳,获得10
12秒前
培根煎蛋堡完成签到 ,获得积分10
12秒前
飘逸小博完成签到,获得积分10
12秒前
sxl完成签到 ,获得积分10
13秒前
13秒前
13秒前
godfrey完成签到,获得积分10
14秒前
14秒前
14秒前
libra完成签到 ,获得积分10
14秒前
科研通AI65的应助被Re采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190478
求助须知:如何正确求助?哪些是违规求助? 9577686
关于积分的说明 21853808
捐赠科研通 7789496
什么是DOI,文献DOI怎么找? 3436407
关于科研通互助平台的介绍 2560235
邀请新用户注册赠送积分活动 2483054